Skip to main content
ELOX logo

ELOX

Eloxx Pharmaceuticals, Inc.
$11.81 -0.09 (-0.76%) At close · Jul 10
Market Cap
$89.45M
Shares
7,573,935

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$11.81 Open$11.51 Day$11.00–12.09 52W$0.00–17.50 Avg vol 30d37K Short int8K · 0.1% float · 1.0d Short vol50% Last earningsNov 9, 2021 DataJan 2020–Jul 2026 Filing10-Q · May 5
Up next
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed May 5, 2026
Equibles Rating blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Very Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 15 · calm Equity put/call 0.55
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +651%
above
Price vs 50-day avg +90%
above
RSI (14) 56
neutral
MACD trend Negative
52-week position 67%
mid-range
Volume (OBV) Bearish div.
distributing
Momentum
relative strength
Very Strong
1-month return +7%
trailing
6-month return +11809900%
trailing
YTD return +11809900%
this year
Relative strength +11809891%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $6 › 200d $2 — 50d above 200d
Institutional flow Flat
0% holders QoQ
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.10% of float · ▲ +94.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
1 holders — near 2-yr low, contrarian setup
Squeeze score 43
elevated · 0–100
Fundamentals
Fair
Revenue growth −100%
Y/Y
EPS growth +42%
Y/Y
Free cash flow $-6.4M
Balance sheet $3.8M
net cash
Quant / Vol
risk profile
Very High
Volatility 101891%
annualized · 1-yr
Max drawdown −100%
past year
ATR 19.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+651% Bullish
Price vs 50-day avg
+90% Bullish
RSI (14)
56 Neutral
MACD trend
Negative Bearish
52-week position
67% Neutral
Volume (OBV)
Bearish div. Bearish
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross) No cross
50d $6 › 200d $2 — 50d above 200d
Institutional flow Flat
0% holders QoQ
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.10% of float · ▲ +94.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
1 holders — near 2-yr low, contrarian setup
Price context
position in its 52-week range
52-wk low $0 Now $12 · 67% 52-wk high $18
vs 200-day avg +651% vs 50-day avg +90%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ELOX
Eloxx Pharmaceuticals, Inc.
this stock
$89.45M +11809900.0% -100.0% 0.1%
ONC
BeOne Medicines Ltd.
$431.70B -1.7% +22179.2% 878.5 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
$123.19B +7.1% +46.2% 28.8 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$69.67B -13.8% +20.8% 16.2 3.3%
ARGX
Argenx SE
$54.85B +4.4% 2.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders
Holders
1
% held
0.0%
Net QoQ
0 sh
Top holder
Towne Trust Company, N.A
Held Float
View
Short & Settlement
Short Interest Rising
Shares short
7.7K
Days to cover
1.0d
Change
+3.8K sh
View
Short Volume
Short vol %
50%
As of
Jul 10, 2026
Short Total
View
Fails to Deliver
FTD shares
1.6K
Value
$19.6K
As of
Jun 12, 2026
View
Off-Exchange
Off-exchange %
100.0%
Week of
May 4, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-6.0M
EPS diluted
$-5.34
View
Buybacks
Remaining
shares 9.2M
View
Filings
SEC Filings
Latest
8-K
Filed
Jun 1, 2026
This year
4
View
Earnings & Events
Earnings Calls
Last call
Nov 9, 2021
View

Performance

5D 20D 120D MTD YTD
ELOX -6.1% +7.4% +11809900.0% -14.9% +11809900.0%
SPY +1.4% +4.1% +9.1% +1.1% +10.7%
vs SPY -7.4% +3.3% +11809890.9% -16.0% +11809889.3%

Capital returns

Buyback program · as of Mar 31, 2026
Authorized
Spent (derived)
Remaining
shares 9.16M

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1035354 CUSIP 29014R301 Visit website